Treatment Allocation in Randomized Trials: Challenges and Best Practices

October 19, 2017

In this free webinar on Treatment Allocation in Randomized Trials, the speakers discussed: Treatment Allocation in Randomized Trials

  • the rationale for the various randomization methods, with illustration from real clinical trials and some considerations about the performance characteristics of the different methods.
  • logistic issues related to the implementation of the various randomization methods.
  • best practices to ensure that this implementation is done in a way that is faithful to the chosen method of randomization and that guarantees the trial integrity from beginning to end, without which the scientific and regulatory aspects of the trial may be jeopardized.



Treatment Allocation in Randomized Trials: Challenges and Best Practices

To access the presentation of this on-demand webinar, register to the right


Randomized trials, which sit at the top of the evidence-based medicine pyramid, are the gold standard approach to establishing causal inference between treatment and outcomes. Both phase 3 trials and randomized phase 2 trials rely on properly conceived and implemented randomization methods, without which selection and accidental bias may preclude firm conclusions. Moreover, phase 1 trials are increasingly randomized in this era of precision medicine and multiple competing treatment schedules that may be developed. Depending on trial size and goals, simple randomization, stratified randomization with permuted blocks, and dynamic methods of treatment allocation, including minimization, can be used to ensure properly balanced treatment arms with respect to known and unknown prognostic factors.  The need for blinding adds a further layer of complexity, and additional issues come into play for randomized trials requiring this feature.


EVERARDO SAADEverardo Saad, MD: Medical Director at the International Drug Development Institute (IDDI).

  • He has over 15 years of experience in Medical Oncology and clinical trial designs.
  • He graduated in Medicine and trained in Internal Medicine in Sao Paulo, and did his fellowship in Medical Oncology at the University of Texas M.D. Anderson Cancer Center, in Houston.
  • After practicing for several years, he shifted his professional career towards education and research in Medical Oncology, and has a special interest in clinical trial methodology, the assessment of endpoints, and the development of novel therapies for cancer patients.


Linda Danielson, MS, Chief Operating Officer, Executive VP at the International Drug Development Institute (IDDI).

  • She holds a MS in biostatistics from the University of Wisconsin, Madison
  • She has been at IDDI since 2006 overseeing all of the operational teams at IDDI including randomization, data management, statistics and project management
  • She co-authored a chapter on randomization in adaptive designs in the book: Practical Considerations for Adaptive Trial Design and Implementation, edited by Weili He, José Pinheiro, Olga M. Kuznetsova, Springer, 2014
  • She is interested in clinical trial design, statistical methods for clinical trials, randomization methods and increasing efficiency in clinical trials through web-based systems.
Webinar Presentation: Treatment Allocation in Randomized Trials: Challenges and Best Practices

To access the presentation of this on-demand webinar, please fill out this form.

    By submitting this form, you agree to receiving commercial electronic messages such as e-mails from IDDI. For more info, please visit our Privacy Policy. You can unsubscribe at any time by clicking the 'unsubscribe' button at the foot of any e-mail communication from IDDI.

    I authorize IDDI to use my data to contact me for commercial purposes.More information